 Molecular Templates, Inc. MTEM the Company or Molecular, a clinical-stage biopharmaceutical company focused on the discovery and development of the Companys proprietary engineered toxin bodies ETBs, which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of 8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of 8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holders option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible preferred stock to be sold in the offering are being sold by Molecular. 